Swixx Biopharma

About:

Swixx Biopharma fully represents biopharma companies in the CEE.

Website: https://www.swixxbiopharma.com/

Top Investors: Citi, UBS, Mérieux Equity Partners, Credit Suisse, HBM Healthcare Investments

Description:

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Total Funding Amount:

102M EUR

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Baar, Zug, Switzerland

Founded Date:

2014-12-01

Contact Email:

info(AT)swixxbiopharma.com

Founders:

Michael Seeley, Petr Nemec, Stuart Swanson

Number of Employees:

1001-5000

Last Funding Date:

2021-12-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai